在罗马尼亚的婴儿中,对帕利维祖马布 (palivizumab) 进行呼吸道同胞病毒预防的坚持
Andreea Calomfirescu-Avramescu1, Adrian Ioan Toma2, Claudia Mehedințu1,3
1Filantropia Clinical Hospital, 011171 Bucharest, Romania.
Vaccines
|February 26, 2025
概括
罗马尼亚 罗马尼亚 罗马尼亚 罗马尼亚
科学领域:
- 儿科 儿科 儿科
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
背景情况:
- 罗马尼亚在2022年启动了一项呼吸道同胞细胞病毒 (RSV) 免疫预防计划.
- 该计划的目标是高危婴儿,包括早产婴儿和患有先天性心脏缺陷或慢性肺病的婴儿.
- 帕利维祖马布是本计划中用于RSV预防的单克隆抗体.
研究的目的:
- 评估罗马尼亚RSV免疫预防计划中对Palivizumab治疗的坚持.
- 在患者和医疗保健提供者的入学方面监测该计划的增长.
- 为了确定影响治疗坚持的因素.
主要方法:
- 从2022年8月到2024年3月,监测患者和专家招生人数.
- 通过与注册患者的电话采访来评估Palivizumab剂量坚持.
- 鉴定疫苗接种完整序列遵守率下降的原因.
主要成果:
- 在2022年8月至2024年3月期间,有1903名患者和233名专家被录取.
- 随着剂量数量的增加,坚持性下降:一剂量99%,两剂量73%,三剂量47%,四剂量35%,五剂量22%.
- 确定了几种因素,有助于减少坚持.
结论:
- 医生和护理人员高度重视RSV免疫预防计划.
- 该计划有效地教育父母关于RSV预防的知识.
- 单克隆抗体用于RSV预防的管理是通过这个程序促进的.
更多相关视频
相关概念视频
Common Respiratory Disorders
205
Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
205
Acute Respiratory Failure-V
113
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
113
Acute Respiratory Failure-IV
116
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
116
Acute Respiratory Failure-II
158
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
158
Acute Respiratory Failure-I
159
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
159
Acute Respiratory Failure-III
151
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
151


